Non-Metastatic Castration-Resistant Prostate Cancer

Section Editor: R. Jonathan Henderson, MD

The latest prostate cancer research is turning its focus on the M0 space. M0 prostate cancer is a stage where the disease is non-metastatic but has become resistant to hormone therapy. Many therapeutic options for castration-resistant prostate cancer are approved and used for metastatic castration-resistant prostate cancer (mCRPC), but fewer options exist for those with non-metastatic (NM) CRPC.




Summarizing the RADAR Guidelines

E. David Crawford, MD, reviews the findings and recommendations of the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) I and II working groups. Phillip J. Koo, MD, then discusses the rationale for RADAR III and the expansion in recommendations from the first two iterations, focusing on updates regarding next generation imaging.
Navigating the M0 Space

Navigating the M0 Space

E. David Crawford, MD, reviews the historical developments in androgen deprivation therapy (ADT) for prostate cancer and the emergence of the non-metastatic castration-resistant, or M0, prostate cancer. He then describes future directions for treatment options for these patients with a focus on androgen pathway inhibitors.

RADAR III | Next Generation Imaging Presentation

E. David Crawford, MD, reviews the history of the efforts of the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Working Group. He then provides an update on the recently published RADAR III manuscript, which focuses on the impact of next generation imaging (NGI) on prostate cancer.
February PCa

PCa Commentary | Volume 131 – February 2019

This Commentary will discuss these developments and the current indications for enzalutamide (ENZ) and new studies of ENZ as monotherapy
Immunotherapy for Castration Resistant Prostate Cancer

Immunotherapy for Castration Resistant Prostate Cancer

Daniel P. Petrylak, MD, provides a brief update on data regarding sipuleucel-T for castration resistant prostate cancer (CRPC), as well as pembrolizumab for microsatellite instability (MSI) -high metastatic prostate cancer patients.
Advanced Disease A Real Need for Shared Care

Advanced Disease — A Real Need for Understanding and Shared Care

Daniel Petrylak, MD, stresses the importance of a multidisciplinary approach when treating prostate cancer. Not only does this mean involving urologists, oncologists, and primary care physicians, but also involving nutritionist, mental health professionals, and pain management experts for maintaining patients’ QOL.

AR-V7 in Castration Resistant Prostate Cancer

Dr. Emmanuel Antonarakis discusses treating chemo-naive metastatic hormone-sensitive prostate cancer and then discusses the impact of AR-V7 in CRPC.



R. Jonathan Henderson, MD
Regional Urology, LLC
Shreveport, Louisiana

Jonathan Henderson, MD, obtained a Bachelor of Science Degree at LSU in Baton Rouge in microbiology. After receiving his M.D. at LSU Medical Center in Shreveport, he completed his internship and residency in Urology at LSUMC Hospital. During this time, he authored a number of papers and presentations. Dr. Henderson spent the next six years in practice in Alabama where he specialized in treating disorders of the female bladder and laparoscopy. During this time, he served as a representative of Alabama to the Southeastern Section of the American Urology Association. He also served as an assistant clinical professor of Urology at the University of Alabama. Dr. Henderson is certified by the American Board of Urology. He is a member of the American Urologic Association, Shreveport Medical Society, Louisiana State Medical Society, the Society of Laparoscopic Surgeons, and the Alpha Omega Alpha Medical Honor Society. He has been on the LUGPA Board of Directors since 2011 and is currently serving as Secretary.


Eleni Efstathiou, MD, PhD
MD Anderson Cancer Center
Houston, Texas

Eleni Efstathiou, MD, PhD is the Associate Professor of the Department of Genitourinary Medical Oncology, Division of Cancer Medicine at the The University of Texas MD Anderson Cancer Center. She earned her MD and PhD from the National and Kapodistrian University of Athens School of Medicine.  She was awarded the Young Investigator Award in 2008 and Career Development Award in 2010 from the Prostate Cancer Foundation. She is a member of the European Society for Medical Oncology, American Society of Clinical Oncology, and American Association for Cancer Research. 

Supported in part by Janssen Biotech.